Check-Cap to merge with MBody AI in embodied AI workforce push
Director Agee Nancy H of Precigen, Inc. (NASDAQ:PGEN), a biotechnology company with a market capitalization of $1.29 billion, purchased 15,000 shares of common stock on September 4, 2025. The shares were bought at a price of $4.60, totaling $69,000. This insider purchase comes as the stock has shown remarkable strength, gaining over 350% in the past year and trading near its 52-week high of $5.22. Following the transaction, Agee directly owns 217,841 shares of Precigen. InvestingPro analysis indicates the stock is currently in overbought territory, with 13 additional key insights available to subscribers.
In other recent news, Precigen has secured $100 million in non-dilutive financing through a credit facility agreement with Pharmakon Advisors, providing the company with significant financial resources. This agreement includes an option to access an additional $25 million by March 2027, with the credit facility maturing five years from the closing date. The financing bears interest at a variable rate of 6.50% plus a three-month SOFR with a 3.75% floor. Furthermore, Cantor Fitzgerald reiterated its Overweight rating on Precigen, expressing a positive outlook on the company. In parallel, H.C. Wainwright maintained its Buy rating and set an $8.50 price target following the FDA’s approval of Papzimeos for treating recurrent respiratory papillomatosis. Precigen has also entered into a supply agreement with Catalent for the manufacturing of PAPIZEMOS, effective August 2025. Additionally, Citizens JMP raised Precigen’s stock price target to $8.00, influenced by the approved pricing for the RRP treatment. These developments mark significant progress for Precigen in both financial and operational aspects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.